MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$3.05 USD
-0.05 (-1.61%)
Updated Apr 26, 2024 03:44 PM ET
After-Market: $3.08 +0.03 (0.98%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MEIP 3.05 -0.05(-1.61%)
Will MEIP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MEIP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MEIP
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer
MEIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
AstraZeneca's (AZN) Imfinzi Early-Stage Lung Cancer Study Fails
Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion
Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises
Other News for MEIP
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (AvastinĀ®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma prioritizes voruciclib, will not continue with 2nd ROC
MEI Pharma reports data from study evaluating ME-344/Avastin combo for mCRC
MEI Pharma shelves plans for a second return of capital